TLN1 Knockout cell line(NB4)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

TLN1 (talin 1) encodes a cytoskeletal protein concentrated at cell-substratum and cell-cell contacts. TLN1 contributes to actin filament assembly, cell spreading, migration, and adhesion to the extracellular matrix. It colocalizes with integrins at the cell surface and contains interaction sites for beta-1 integrin, actin, and vinculin, supporting the organization of adhesion complexes and connections between the plasma membrane and cytoskeleton.

NB4 is a human acute promyelocytic leukemia (APL; AML FAB M3) cell line established from the bone marrow of a patient with relapsed disease. The cells harbor the characteristic t(15;17) chromosomal translocation resulting in the PML-RARA fusion gene. NB4 cells exhibit promyelocytic characteristics and are widely used as a model for studying acute promyelocytic leukemia biology, differentiation mechanisms, and targeted therapeutic responses.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.